fbpx

GBM Awareness Day is July 17. Join us in raising awareness all month long! Learn more.

MindMatters White Logo

Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.

Subscribe to MindMatters

American Brain Tumor Association Announces New Board of Directors Officers and Members

Laura Aguilar

Chicago, IL (February 27, 2024)—The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors. They will advance the ABTA mission under the leadership of Ram Subramanian, Board Chair, and Ralph DeVitto, President and CEO. Their terms began on January 1, 2024.

“Over the past year, the American Brain Tumor Association has experienced tremendous growth, demonstrating the impact of our board’s vision and commitment,” DeVitto said. “As we welcome our new members, we are certain their contributions will help us ‘Meet Hope Head On’ by tripling our research investment, doubling our patient support, and advocating to double federal research funding for brain tumors.”

New members joining the Board are:

Laura Aguilar, M.D., Ph.D.

As a biotech entrepreneur and physician-scientist, Laura has dedicated her career to advancing medical treatments for cancer and addressing unmet medical needs. She earned her medical degree and Ph.D. in Immunology from Baylor College of Medicine, followed by specialized training in Pediatrics and Pediatric Oncology at Texas Children’s Hospital in Houston. Later, she continued her academic pursuits at Harvard Medical School, conducting research in gene- and cell-based therapies while serving as an attending physician at the Dana-Farber Cancer Institute and Boston Children’s Hospital.

Laura co-founded Advantagene, Inc. (later Candel Therapeutics), focusing on developing gene-based immuno-oncology products, initially targeting brain and prostate cancer. As Chief Medical Officer, Laura played a pivotal role in guiding the company from its inception to a successful IPO, overseeing Phase 1 to Phase 3 studies that have enrolled thousands of cancer patients.

Charles “Chad” Schafer, J.D.

Chad is a Partner in the Litigation Group of Sidley Austin LLP—an international law firm with 21 locations across nine countries. He has focused his practice on representing corporations at trial and on appeal in a diverse range of civil litigation matters, in state and federal courts throughout the country.

Chad’s late wife, Juliana Sanchez Schafer, was diagnosed with a brain tumor in 2004, and worked as a tireless advocate for the ABTA until her passing in August 2021. With Juliana’s passing, Chad has taken on the mantle of fighting to find better treatments, and some day a cure, for brain tumors.

The 2024 ABTA Board of Directors Officers and Members:  

Ram Subramanian—Chair; Bob Kruchten—Vice Chair; Mindee Plugues—Secretary; Danny Monson—Treasurer; Jim Reilly—Immediate Past Chair; and Members—Laura Aguilar, M.D., Ph.D.; Srisupen Andersen, CFA; Mitchel S. Berger, M.D.; Charles Schafer, J.D., and Patti Tsai-Steiner. 

President & CEO  

Ralph A. DeVitto 

Founders  

Susan Netchin Kramer—Founder  

Linda Gene Goldstein—Co-Founder 


 

Make a Difference Today

Your generosity fuels progress. The American Brain Tumor Association has already invested over $35 million in life-changing brain tumor research, leading to breakthroughs like the FDA approval of vorasidenib, a groundbreaking treatment for low-grade glioma. Let’s come together to create more breakthroughs.

🤍 Join us in bringing hope and advancing care. Donate now.

Share This Content:

Share:

More Posts

Upcoming Events

Educational Resources

Always free for patients & caregivers

Gina & Tim Abbas
Caregiver & Anaplastic Astrocytoma Survivor

Your Gift Matched!

Make an end-of-year gift now and your gift will be matched thanks to the family of Connie Fischer.